Program
sotorasib
Also written as “Sotorasib”, “AMG 510” and “avutometinib and sotorasib”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Noonan Syndrome, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgen | 244 open or running | phase 3since Mar 5, 2020 | Jun 26, 2018 | Dec 17, 2026phase 1 · NCT04185883 |
| Criterium | 10 open or running | phase 2since Dec 6, 2021 | Dec 6, 2021 | none ahead |
| Effector Therapeutics | 11 open or running | phase 2since Sep 10, 2019 | Sep 10, 2019 | none ahead |
| Erasca | 10 open or running | phase 1since Jul 2, 2021 | Jul 2, 2021 | none ahead |
| Verastem | 11 open or running | phase 2since Sep 29, 2021 | Sep 29, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 6 studies since Jun 26, 2018.
- Jun 14, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungAmgen · NCT04933695 · 42 enrolled · United States, Belgium, Denmark and more
- Jul 2, 2021Erasca's first study: phase 1 study in Noonan SyndromeNew to ErascaErasca · NCT04959981 · 24 enrolled · United States
- Sep 7, 20212 phase 1 studies in Healthy ParticipantsAmgen · NCT05045638, NCT05048784
- Sep 29, 2021Verastem's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to VerastemVerastem · NCT05074810 · 153 enrolled · United States, Belgium, France and more
- Dec 6, 2021Criterium's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to CriteriumCriterium · NCT05180422 · United States
- Jan 6, 2022Phase 3 study in Colorectal NeoplasmsAmgen · NCT05198934 · 160 enrolled · United States, Australia, France and more
- Apr 7, 2022Phase 1 study in Healthy ParticipantsAmgen · NCT05327491 · 146 enrolled · United States
- Aug 3, 2022Phase 1 study in Healthy VolunteersAmgen · NCT05497557 · 16 enrolled · United States
- Sep 19, 2022Phase 1 study in Healthy VolunteersAmgen · NCT05550129 · 13 enrolled · United States
- Oct 3, 20228 phase 1 studiesAmgen · NCT05568082, NCT05571163, NCT05577624 and 5 more
- May 23, 2023Phase 3 study in Carcinoma, Non-Small-Cell LungAmgen · NCT05920356 · 750 planned · United States, Argentina, Australia and more
- Sep 25, 2023Phase 1 study in Healthy ParticipantsAmgen · NCT06061523
- Jan 15, 2024Phase 3 study in Colorectal NeoplasmsAmgen · NCT06252649 · 450 planned · United States, Argentina, Australia and more
- Sep 8, 2025Phase 2 study in Advanced Solid TumorsAmgen · NCT07172919 · 14 planned · United States, Australia, France and more
Ahead
- Dec 17, 2026Primary completion: phase 1 study in Advanced Solid TumorsAmgen · NCT04185883
- Jun 30, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungAmgen · NCT05920356
- Jul 1, 2028Primary completion: phase 2 study in Advanced Solid TumorsAmgen · NCT07172919
- Sep 25, 2028Primary completion: phase 3 study in Colorectal NeoplasmsAmgen · NCT06252649
TargetBeta
“An orally available inhibitor of the specific KRAS mutation, p.G12C, ”NCIt, by rule
“GTPase KRas inhibitor”ChEMBL 37, by rule
Other programs on KRAS
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| adagrasibrule | Bristol-Myers Squibb | phase 3 | 16 |
| olomorasib | Eli Lilly | phase 3 | 16 |
| divarasib | Hoffmann-La Roche | phase 3 | 13 |
| KRAS G12D Inhibitor VS-7375rule | Genfleet Therapeutics (Shanghai) | phase 3 | 12 |
| glecirasibrule | Allist Pharmaceuticals | phase 3 | 12 |
| calderasib | Merck | phase 3 | 12 |
| daraxonrasibrule | Revolution Medicines | phase 3 | 10 |
| garsorasibrule | InventisBio | phase 3 | 8 |
| KRAS G12D Inhibitor HRS-4642 | Jiangsu HengRui Medicine | phase 3 | 7 |
| zoldonrasibrule | Revolution Medicines | phase 3 | 6 |
| HRS-7058 | Jiangsu HengRui Medicine | phase 3 | 6 |
| opnurasibrule | Novartis | phase 3 | 5 |
Studies
All 28 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07172919Advanced Solid Tumors · United States, Australia, France and more | 2 | Recruiting | Amgen | Jul 1, 2028 | 14 |
| NCT06252649Colorectal Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Amgen | Sep 25, 2028 | 450 |
| NCT06061523Healthy Participants | 1 | Withdrawn | Amgen | Sep 9, 2024 | 0 |
| NCT05920356Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Recruiting | Amgen | Jun 30, 2027 | 750 |
| NCT05599828Healthy Participants · United States | 1 | Completed | Amgen | Sep 13, 2020 | 14 |
| NCT05598281Healthy Participants · United States | 1 | Completed | Amgen | Nov 19, 2019 | 14 |
| NCT05581992Healthy Participants · United States | 1 | Completed | Amgen | Jan 26, 2020 | 14 |
| NCT05581758Healthy Participants · United States | 1 | Completed | Amgen | Nov 25, 2019 | 14 |
| NCT05578859Healthy Subjects · United States | 1 | Completed | Amgen | Mar 24, 2020 | 8 |
| NCT05577624Healthy Participants · United States | 1 | Completed | Amgen | Dec 1, 2019 | 14 |
| NCT05571163Healthy Participants · United States | 1 | Completed | Amgen | Jun 14, 2020 | 13 |
| NCT05568082Healthy Participants · United States | 1 | Completed | Amgen | Dec 17, 2019 | 14 |
| NCT05550129Healthy Volunteers · United States | 1 | Completed | Amgen | Nov 25, 2019 | 13 |
| NCT05497557Healthy Volunteers · United States | 1 | Completed | Amgen | Sep 8, 2022 | 16 |
| NCT05327491Healthy Participants · United States | 1 | Completed | Amgen | Jul 17, 2022 | 146 |
| NCT05198934Colorectal Neoplasms · United States, Australia, France and more | 3 | Completed | Amgen | Jul 16, 2025 | 160 |
| NCT05180422Carcinoma, Non-Small-Cell Lung · United States | 2 | Withdrawn | Criterium | Jan 31, 2023 | 0 |
| NCT05074810Carcinoma, Non-Small-Cell Lung · United States, Belgium, France and more | 2 | Active, not recruiting | Verastem | Jun 2026 | 153 |
| NCT05048784Healthy Participants · United States | 1 | Completed | Amgen | Feb 18, 2022 | 145 |
| NCT05045638Healthy Participants · United States | 1 | Completed | Amgen | Oct 10, 2021 | 13 |
| NCT04959981Noonan Syndrome · United States | 1 | Completed | Erasca | Apr 27, 2023 | 24 |
| NCT04933695Carcinoma, Non-Small-Cell Lung · United States, Belgium, Denmark and more | 2 | Terminated | Amgen | May 28, 2025 | 42 |
| NCT04887064Hepatic Impairment · United States | 1 | Completed | Amgen | Mar 9, 2022 | 20 |
| NCT04380753Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation · Hong Kong, Taiwan | 1 | Completed | Amgen | Dec 31, 2021 | 12 |
| NCT04303780KRAS p, G12c Mutated /Advanced Metastatic NSCLC · United States, Australia, Belgium and more | 3 | Completed | Amgen | Aug 2, 2022 | 345 |
| NCT04185883Advanced Solid Tumors · United States, Australia, Austria and more | 1 | Active, not recruiting | Amgen | Dec 17, 2026 | 610 |
| NCT04092673Solid Tumor, Adult · United States | 2 | Recruiting | Effector Therapeutics | Dec 31, 2024 | 30 |
| NCT03600883KRAS p.G12C Mutant Advanced Solid Tumors · United States, Australia, Austria and more | 2 | Completed | Amgen | May 29, 2026 | 713 |
How it is read
Names in the registry
- “Sotorasib”, 14 entries
- “AMG 510”, 12 entries
- “sotorasib”, 1 entry
- “avutometinib and sotorasib”, 1 entry
- “avutometinib and sotorasib and defactinib”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Colorectal Neoplasms, 2 studies
- Noonan Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.